Chemcrux Enterprises has appointed Zarna Pankaj Thakar as an Additional Director (Non-Executive, Independent) effective August 4, 2026. The Board of Directors approved the appointment during a meeting held on Tuesday, August 4, 2026, at the company’s registered office in Vadodara. This move strengthens the independent oversight on the board, with Thakar’s appointment subject to regularisation by shareholders at the ensuing Annual General Meeting (AGM).

The appointment was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Dipika Rajpal, Company Secretary & Compliance Officer, signed the disclosure submitted to BSE Limited.

Appointment Details

Thakar, who holds DIN 11869662, will serve for a term of one year from August 4, 2026, to August 3, 2027. As an additional director, she is not liable to retire by rotation. Her remuneration will consist of sitting fees for attending Board or Committee meetings, as fixed by the Board of Directors from time to time, along with any other payments approved by the Board or members as per applicable laws.

Profile and Qualifications

Zarna Pankaj Thakar is a practicing Cost and Management Accountant (CMA) and the founder of Zarna Thakar & Associates. She holds a US CMA certification and a Bachelor of Commerce degree. With over 10 years of experience, she has advised listed companies, multinational corporations, and manufacturing organizations on financial oversight, strategic cost management, internal financial controls, SAP S/4HANA and ERP governance, business transformation, profitability enhancement, capital investment evaluation, manufacturing operations, ESG, and internal and cost audits.

She currently holds no other directorships in listed entities and has not resigned from any listed entity in the past three years. Per BSE Circular no. LIST/COMP/14/2018-19 dated June 20, 2018, she is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

Chemcrux Enterprises reported a 135% year-on-year increase in standalone net profit to ₹137.43 lakh for the quarter ended June 30, 2026, driven by a 31% surge in revenue from operations. The Vadodara-based bulk drug intermediate manufacturer saw its consolidated net profit attributable to owners jump 444% to ₹50.52 lakh during the same period. The Board of Directors approved these unaudited financial results on August 4, 2026, alongside the Limited Review Report from statutory auditors Naresh & Co.

Revenue from operations stood at ₹2,193.81 lakh on a standalone basis, up from ₹1,674.74 lakh in the corresponding quarter of FY26. On a consolidated basis, which includes wholly-owned subsidiary Kalichem Private Limited, revenue was ₹2,193.82 lakh, compared to ₹1,650.35 lakh in Q1FY26. The company’s total comprehensive income for the quarter reached ₹159.22 lakh standalone and ₹72.31 lakh consolidated.

Financial Performance Highlights

The improvement in profitability was supported by controlled cost structures despite higher material consumption. Standalone cost of materials consumed rose to ₹827.51 lakh from ₹552.72 lakh in Q1FY25, while employee benefits expense increased to ₹259.05 lakh from ₹201.99 lakh. Other expenses remained stable at ₹655.12 lakh compared to ₹434.79 lakh in the previous year, reflecting operational scaling.

Basic earnings per share (EPS) improved to ₹0.93 from ₹0.39 on a standalone basis. Consolidated basic EPS rose to ₹0.34 from ₹0.06. Diluted EPS remained identical to basic EPS due to the negligible impact of employee stock options, as disclosed under Ind AS 33.

Corporate Governance and Disclosures

The Board meeting, held at the company’s registered office in Vadodara, also scheduled the 30th Annual General Meeting for September 17, 2026, via video conferencing. Dipika Rajpal, Company Secretary & Compliance Officer, signed the disclosure submitted to BSE Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Naresh & Co., Chartered Accountants, issued their limited review report stating that nothing came to their attention to suggest the statements contained material misstatements. The audit covered both standalone and consolidated results, including procedures for the subsidiary Kalichem Private Limited.

What the Numbers Show

The significant divergence between standalone and consolidated profit growth warrants attention. While standalone PAT surged 135%, consolidated PAT jumped over 440%. This suggests that the subsidiary, Kalichem Private Limited, may have contributed disproportionately to the bottom-line improvement or benefited from specific one-time gains not reflected in the parent entity’s standalone figures. Additionally, the company granted 1,07,700 Employee Stock Options on May 15, 2026, under the ESOP 2025 Scheme, with associated expenses recognized in the current quarter. The implementation of the New Labour Codes effective November 21, 2025, did not materially impact the financial results, as employee benefit structures were already aligned with the new framework.